# Lecture 05: Bleeding Disorders
## Unit 2.9: Hematology and Oncology
---
## Learning Objectives
By the end of this lecture, students will be able to:
1. Describe the normal hemostatic process
2. Explain the evaluation of a bleeding patient
3. Describe platelet disorders (quantitative and qualitative)
4. Explain coagulation factor deficiencies (hemophilia, vWD)
5. Describe acquired coagulation disorders (DIC, liver disease, vitamin K)
6. Explain the approach to abnormal coagulation tests
---
## Lecture Outline
### I. Normal Hemostasis
Hemostasis is the physiologic process that prevents blood loss following vascular injury through a coordinated sequence of vascular, platelet, and coagulation responses. This process can be conceptualized as occurring in three overlapping phases that work together to form a stable clot while avoiding excessive thrombosis. Primary hemostasis involves vasoconstriction and platelet plug formation, providing the initial response to injury within seconds to minutes. Secondary hemostasis involves activation of the coagulation cascade to generate thrombin and form a fibrin mesh that stabilizes the platelet plug. Fibrinolysis eventually breaks down the clot once vessel healing is complete, preventing permanent occlusion.
Primary hemostasis begins immediately following endothelial injury and involves the vessel wall, platelets, and von Willebrand factor working together to form the initial platelet plug. Vasoconstriction, mediated by endothelin released from damaged endothelium and by neural reflexes, provides the first response by reducing blood flow to the injured area. Platelet adhesion occurs when von Willebrand factor bridges exposed subendothelial collagen to platelet glycoprotein Ib receptors, anchoring platelets at the injury site. Activated platelets undergo shape change and release granule contents including ADP and thromboxane A2 that recruit and activate additional platelets. Platelet aggregation follows as fibrinogen bridges adjacent platelets via glycoprotein IIb/IIIa receptors, forming the initial platelet plug.
Secondary hemostasis involves activation of the coagulation cascade through two converging pathways that generate thrombin, the central enzyme of coagulation. The extrinsic pathway is initiated when tissue factor exposed at the injury site binds factor VII, forming a complex that activates factor X. The intrinsic pathway involves sequential activation of factors XII, XI, IX, and VIII, culminating in factor X activation through a separate route. The common pathway proceeds from factor X through prothrombin to thrombin, which then converts fibrinogen to fibrin monomers that polymerize into an insoluble mesh. Factor XIII cross-links fibrin strands, stabilizing the clot and making it resistant to fibrinolysis.
Several key components and concepts underlie the hemostatic process and its clinical assessment. Thrombin serves as the central enzyme, not only cleaving fibrinogen to fibrin but also activating platelets and amplifying the coagulation cascade through positive feedback loops. Vitamin K-dependent factors include II, VII, IX, and X, as well as the anticoagulant proteins C and S, all requiring vitamin K for gamma-carboxylation essential to their function. Calcium ions are required as cofactors throughout the coagulation cascade. Understanding these components explains the effects of vitamin K deficiency and warfarin anticoagulation. The natural anticoagulants including antithrombin, protein C, and protein S prevent excessive clot formation and maintain hemostatic balance.
Panel A: Schematic of primary hemostasis showing vasoconstriction, platelet adhesion via von Willebrand factor, activation with granule release, and aggregation via fibrinogen bridges. Panel B: Coagulation cascade diagram showing extrinsic pathway initiated by tissue factor, intrinsic pathway with contact factors, and common pathway through factor X to thrombin and fibrin. Panel C: Illustration of stable clot structure with cross-linked fibrin mesh reinforcing the platelet plug. Panel D: Balance diagram showing procoagulant and anticoagulant factors in hemostatic equilibrium.
---
### II. Evaluation of Bleeding
Clinical assessment of a bleeding patient begins with distinguishing primary from secondary hemostatic defects based on bleeding patterns, as this distinction guides subsequent laboratory evaluation. Primary hemostatic defects involving platelets or von Willebrand factor produce mucocutaneous bleeding including petechiae, purpura, epistaxis, gingival bleeding, menorrhagia, and gastrointestinal hemorrhage. Bleeding occurs immediately after injury and responds well to local pressure. Secondary hemostatic defects involving coagulation factors produce deep tissue bleeding including hemarthrosis, muscle hematomas, and retroperitoneal hemorrhage. Bleeding onset is often delayed hours after injury and responds poorly to pressure, requiring factor replacement for control.
The bleeding history provides essential information for distinguishing inherited from acquired disorders and identifying the likely defect type. Family history of bleeding suggests inherited disorders, with inheritance pattern providing clues to the specific diagnosis. Age of onset differentiates congenital conditions presenting in childhood from acquired disorders developing later. The response to hemostatic challenges including surgery, dental extractions, and trauma provides objective evidence of bleeding tendency. In women, menstrual history quantifying flow and duration helps identify significant menorrhagia suggesting an underlying disorder. Medication history must include anticoagulants, antiplatelets, and NSAIDs that affect hemostasis.
Initial laboratory testing includes platelet count and coagulation screening tests that evaluate different aspects of the hemostatic system. Platelet count assesses platelet number but not function. The prothrombin time assesses the extrinsic and common pathways, reflecting factors VII, X, V, II, and fibrinogen, and is reported as the international normalized ratio for standardization. The activated partial thromboplastin time assesses the intrinsic and common pathways, reflecting factors XII, XI, IX, VIII, X, V, II, and fibrinogen. Bleeding time, a global measure of primary hemostasis, is rarely used clinically due to poor standardization. The platelet function analyzer provides a screening test for platelet function and von Willebrand factor activity.
Additional specialized testing is guided by initial results and clinical suspicion. Fibrinogen level quantifies this factor, which may be decreased in DIC, liver disease, or inherited deficiency. Thrombin time measures the conversion of fibrinogen to fibrin, prolonged by low or dysfunctional fibrinogen, heparin, or fibrin degradation products. Mixing studies combining patient plasma with normal plasma distinguish factor deficiencies, which correct, from inhibitors, which do not correct. Specific factor assays measure individual coagulation factor activity when deficiency is suspected. von Willebrand factor studies including antigen level, activity (ristocetin cofactor), and multimer analysis diagnose and classify von Willebrand disease.
Panel A: Comparison of bleeding patterns in primary versus secondary hemostatic defects showing typical sites and characteristics. Panel B: Flowchart for systematic bleeding history including family history, surgical challenges, menstrual history, and medications. Panel C: Diagram showing which coagulation tests assess which parts of the cascade with PT evaluating extrinsic/common and aPTT evaluating intrinsic/common pathways. Panel D: Algorithm for interpreting initial coagulation tests and directing subsequent specialized testing.
---
### III. Thrombocytopenia
Thrombocytopenia, defined as platelet count below 150,000 per microliter, results from decreased production, increased destruction, or sequestration, with the mechanism determining both prognosis and treatment approach. Decreased production occurs with bone marrow failure from aplastic anemia, myelodysplasia, or infiltrative processes, as well as from drugs suppressing megakaryopoiesis. Increased destruction may be immune-mediated as in immune thrombocytopenia or thrombotic microangiopathies, or non-immune from mechanical destruction or consumption. Sequestration in an enlarged spleen reduces circulating platelets despite normal total body platelet mass. Dilutional thrombocytopenia occurs with massive transfusion of red cells without platelet replacement.
Immune thrombocytopenia results from autoantibodies binding to platelet surface glycoproteins, typically GPIIb/IIIa or GPIb, leading to accelerated platelet clearance by splenic macrophages. Primary ITP occurs without identifiable underlying cause and may be acute, particularly in children following viral illness where spontaneous resolution is common, or chronic in adults where the disease often persists. Secondary ITP occurs in association with systemic lupus erythematosus, HIV infection, hepatitis C virus, drugs, or lymphoproliferative disorders that must be identified and addressed. Diagnosis requires exclusion of other causes of thrombocytopenia since there is no specific confirmatory test. The peripheral blood smear shows decreased platelets that are often large, reflecting increased production of young platelets.
Treatment of ITP depends on platelet count, bleeding symptoms, and planned procedures. Observation alone is appropriate for asymptomatic patients with platelet counts above 30,000 per microliter since bleeding risk is minimal. Corticosteroids serve as first-line therapy for symptomatic disease or lower platelet counts, with prednisone at 1 milligram per kilogram daily typically producing response within days. Intravenous immunoglobulin provides rapid but temporary platelet increase, useful for acute bleeding or pre-procedure preparation. For chronic or refractory ITP, thrombopoietin receptor agonists including romiplostim and eltrombopag stimulate platelet production and have become second-line therapy. Rituximab targeting B cells produces sustained responses in a subset of patients. Splenectomy, historically second-line treatment, now serves as third-line option with approximately 60 percent long-term cure rate.
Heparin-induced thrombocytopenia represents a unique and dangerous form of drug-induced thrombocytopenia characterized paradoxically by thrombosis rather than bleeding. Antibodies form against complexes of platelet factor 4 and heparin, binding to platelets and activating them, causing both platelet consumption and a prothrombotic state. The typical presentation occurs 5 to 10 days after heparin initiation with a platelet count drop exceeding 50 percent from baseline. Venous and arterial thrombosis may occur, including deep vein thrombosis, pulmonary embolism, and limb-threatening arterial occlusion. Diagnosis relies on clinical probability scoring using the 4Ts system combined with immunologic testing for anti-PF4/heparin antibodies and functional testing. Management requires immediate cessation of all heparin products and initiation of an alternative anticoagulant such as argatroban, bivalirudin, or fondaparinux.
Panel A: Classification diagram of thrombocytopenia by mechanism showing decreased production, increased destruction, and sequestration with representative causes. Panel B: Pathophysiology of immune thrombocytopenia showing antiplatelet antibody binding, Fc receptor-mediated splenic clearance, and compensatory megakaryopoiesis. Panel C: Treatment algorithm for ITP based on platelet count and symptoms from observation through steroids, IVIG, TPO agonists, and splenectomy. Panel D: Mechanism of heparin-induced thrombocytopenia showing PF4-heparin complex, antibody formation, and platelet activation leading to thrombosis.
---
### IV. Qualitative Platelet Disorders
Inherited platelet function disorders result from defects in adhesion receptors, aggregation receptors, or granule contents that impair normal platelet responses despite adequate platelet numbers. Bernard-Soulier syndrome involves deficiency or dysfunction of the GPIb-IX-V complex required for von Willebrand factor-mediated adhesion to subendothelium. This autosomal recessive disorder produces giant platelets visible on blood smear, moderate to severe bleeding, and failure to aggregate in response to ristocetin while other aggregation responses remain normal. Glanzmann thrombasthenia involves deficiency of GPIIb/IIIa, the fibrinogen receptor required for platelet aggregation. Patients have normal platelet count and size but absent aggregation to all agonists except ristocetin, since adhesion remains intact. Both conditions produce significant mucocutaneous bleeding requiring platelet transfusion or recombinant factor VIIa for treatment.
Storage pool disorders encompass defects in dense granules, alpha granules, or both, resulting in impaired granule content release during platelet activation. Dense granule deficiency produces decreased ADP, ATP, serotonin, and calcium, limiting secondary wave aggregation and recruitment of additional platelets. Hermansky-Pudlak syndrome combines delta granule deficiency with oculocutaneous albinism and pulmonary fibrosis. Gray platelet syndrome results from alpha granule deficiency, producing characteristic gray-appearing platelets on smear due to loss of granule contents. Clinical bleeding in storage pool disorders is generally mild to moderate, and diagnosis requires electron microscopy or specialized platelet function testing.
Acquired platelet dysfunction occurs commonly with medications and systemic disease, often producing clinically significant bleeding when platelet count alone would not explain symptoms. Aspirin irreversibly inhibits cyclooxygenase-1, preventing thromboxane A2 synthesis essential for platelet activation, with effects lasting the platelet lifespan of 7 to 10 days. P2Y12 receptor inhibitors including clopidogrel, prasugrel, and ticagrelor block ADP-mediated platelet activation and are used for cardiovascular prevention. Other NSAIDs reversibly inhibit cyclooxygenase with effects lasting only until drug clearance. Uremia produces multifactorial platelet dysfunction through accumulated uremic toxins affecting multiple aspects of platelet function. Myeloproliferative neoplasms produce qualitatively abnormal platelets predisposing to both bleeding and thrombosis.
Uremic bleeding deserves special attention given its clinical importance and unique management requirements. The pathophysiology involves multiple mechanisms including impaired platelet adhesion, decreased von Willebrand factor activity, and accumulation of uremic toxins that interfere with platelet function. Bleeding time is characteristically prolonged, though this test is rarely performed clinically. Treatment options include dialysis to remove uremic toxins, which provides the most effective long-term improvement. DDAVP releases von Willebrand factor and factor VIII from endothelial stores, providing temporary improvement for 4 to 6 hours useful for acute bleeding or pre-procedural preparation. Cryoprecipitate provides von Willebrand factor and fibrinogen. Conjugated estrogens produce a delayed but prolonged effect through unclear mechanisms. Maintaining hematocrit above 30 percent improves platelet-endothelium interaction.
Panel A: Comparison of Bernard-Soulier syndrome with GPIb deficiency affecting adhesion versus Glanzmann thrombasthenia with GPIIb/IIIa deficiency affecting aggregation. Panel B: Platelet granule contents diagram showing dense granule components and alpha granule components with clinical effects of their deficiency. Panel C: Sites of action for antiplatelet drugs showing aspirin inhibiting cyclooxygenase, P2Y12 inhibitors blocking ADP receptors, and GPIIb/IIIa inhibitors blocking aggregation. Panel D: Pathophysiology and treatment options for uremic bleeding including dialysis, DDAVP, and cryoprecipitate.
---
### V. von Willebrand Disease
von Willebrand disease is the most common inherited bleeding disorder, affecting approximately 1 percent of the population, caused by quantitative or qualitative defects in von Willebrand factor. This large multimeric glycoprotein serves two essential hemostatic functions. First, von Willebrand factor mediates platelet adhesion to injured subendothelium by binding to both exposed collagen and platelet GPIb, bridging platelets to the vessel wall. Second, von Willebrand factor serves as the carrier protein for factor VIII, protecting it from premature degradation and maintaining circulating factor VIII levels. Inheritance is typically autosomal dominant for types 1 and 2, while type 3 with complete absence of von Willebrand factor is autosomal recessive.
Type 1 von Willebrand disease, accounting for 70 to 80 percent of cases, involves partial quantitative deficiency with proportional reduction in both von Willebrand factor antigen and activity. Clinical severity correlates with the degree of deficiency, with many patients experiencing mild mucocutaneous bleeding including epistaxis, menorrhagia, and excessive bleeding after dental procedures or surgery. Type 2 variants involve qualitative defects with disproportionate reduction in function relative to antigen level. Type 2A features decreased high-molecular-weight multimers that are most hemostatically active. Type 2B involves increased affinity for platelet GPIb, causing spontaneous binding and clearance of both platelets and large multimers. Type 2M has decreased platelet binding without multimer abnormality. Type 2N has decreased factor VIII binding, mimicking mild hemophilia. Type 3 involves complete absence of von Willebrand factor, producing severe bleeding with very low factor VIII levels.
Diagnosis requires a panel of specialized tests that together characterize the defect. von Willebrand factor antigen measures total circulating protein. Ristocetin cofactor activity measures functional ability to agglutinate platelets, with the ratio of activity to antigen distinguishing quantitative from qualitative defects. Factor VIII activity is decreased secondary to its dependence on von Willebrand factor as carrier. Multimer analysis by gel electrophoresis identifies loss of high-molecular-weight multimers characteristic of type 2A and 2B. Testing should be performed away from acute illness, surgery, or stress, as these conditions can temporarily elevate von Willebrand factor levels and mask the diagnosis. Blood type affects levels, with type O individuals having lower baseline values.
Treatment depends on the specific type of von Willebrand disease and the clinical situation. DDAVP releases endothelial stores of von Willebrand factor and factor VIII, producing temporary increases lasting 6 to 12 hours. This agent works well for type 1 and some type 2 variants but is contraindicated in type 2B where it may worsen thrombocytopenia by releasing abnormal von Willebrand factor. A DDAVP trial to confirm response should be performed before relying on it for clinical situations. von Willebrand factor concentrates containing both von Willebrand factor and factor VIII are used for type 3, type 2B, severe type 2 variants, and patients unresponsive to DDAVP. Antifibrinolytic agents including aminocaproic acid and tranexamic acid serve as adjuncts for mucosal bleeding. Combined oral contraceptives reduce menorrhagia in affected women.
Panel A: Dual function of von Willebrand factor showing platelet adhesion mediation and factor VIII carrier function with clinical consequences of deficiency. Panel B: Classification of von Willebrand disease types comparing quantitative deficiency in types 1 and 3 versus qualitative defects in type 2 variants. Panel C: Multimer analysis patterns showing normal distribution versus loss of high-molecular-weight multimers in type 2A and 2B. Panel D: Treatment algorithm based on von Willebrand disease type showing DDAVP for type 1, von Willebrand concentrate for types 2B and 3, and adjunctive antifibrinolytics.
---
### VI. Hemophilia
Hemophilia A and B are X-linked recessive disorders caused by deficiency of factor VIII and factor IX, respectively, producing indistinguishable clinical phenotypes of deep tissue bleeding. Hemophilia A, affecting approximately 1 in 5,000 males, is the more common form, while hemophilia B (Christmas disease) affects approximately 1 in 30,000 males. Carrier females may have reduced factor levels depending on X-inactivation patterns but rarely experience significant bleeding. Spontaneous mutations account for approximately 30 percent of cases, occurring in families without prior history. Clinical severity correlates directly with factor level, ranging from severe disease with spontaneous bleeding to mild disease bleeding only with major trauma or surgery.
Severity classification based on factor activity level predicts clinical phenotype and guides management approach. Severe hemophilia with factor levels below 1 percent produces spontaneous hemarthrosis and muscle bleeding, typically manifesting in early childhood when the child begins crawling and walking. Moderate hemophilia with factor levels of 1 to 5 percent causes bleeding with minor trauma but rarely spontaneous hemorrhage. Mild hemophilia with factor levels of 5 to 40 percent may go undiagnosed until significant hemostatic challenge reveals the bleeding tendency. The joints most commonly affected by hemarthrosis include the knees, elbows, and ankles, and recurrent bleeding causes hemophilic arthropathy with chronic pain and disability.
Clinical manifestations reflect the secondary hemostatic defect with delayed, deep tissue bleeding. Hemarthrosis presents with joint pain, swelling, and warmth, requiring prompt factor replacement to prevent progression. Repeated hemarthrosis without adequate treatment leads to synovial hypertrophy, chronic inflammation, and destructive arthropathy. Muscle hematomas may cause compartment syndrome or nerve compression. Intracranial hemorrhage represents the most serious manifestation, occurring spontaneously or after minimal trauma, and requires immediate factor replacement and neuroimaging. Pseudotumors, blood cysts from unresolved hematomas, may erode bone or compress structures. Post-surgical bleeding characteristically begins hours after the procedure when the initial platelet plug breaks down.
Treatment has evolved dramatically from plasma-derived products through recombinant factors to novel non-factor therapies. Factor concentrate replacement provides the foundation of treatment, with dosing based on desired factor level increase and factor pharmacokinetics. For factor VIII, the dose in units equals body weight in kilograms multiplied by desired percentage increase multiplied by 0.5, reflecting its intravascular distribution. For factor IX, the multiplier is 1.0 due to greater extravascular distribution. Extended half-life products using PEGylation or Fc fusion allow less frequent dosing. Prophylactic factor administration, starting in early childhood and continuing indefinitely, prevents joint damage and is now standard of care for severe hemophilia. Emicizumab, a bispecific antibody mimicking factor VIII function, has transformed hemophilia A management by providing effective prophylaxis with subcutaneous dosing. Gene therapy approaches are showing promise in clinical trials.
Panel A: X-linked inheritance pattern showing carrier mother transmission to affected sons and carrier daughters. Panel B: Severity classification with factor levels, clinical phenotypes, and corresponding bleeding patterns from spontaneous to trauma-induced. Panel C: Hemophilic arthropathy progression from acute hemarthrosis through synovial hypertrophy to destructive joint disease. Panel D: Evolution of hemophilia treatment from plasma through recombinant factors to emicizumab and gene therapy with timeline of major advances.
---
### VII. Other Inherited and Rare Factor Deficiencies
Factor XI deficiency, also called hemophilia C, differs from hemophilia A and B in its autosomal inheritance and poor correlation between factor level and bleeding severity. This condition occurs with increased frequency in Ashkenazi Jewish populations, affecting up to 4 percent as carriers. Unlike hemophilia A and B, spontaneous hemarthrosis is rare, and bleeding occurs primarily with surgery and trauma, particularly procedures involving tissues with high fibrinolytic activity such as oral and urologic surgery. The variability in bleeding phenotype complicates management, as some patients with very low factor XI levels experience minimal bleeding while others with moderate deficiency bleed significantly. Treatment options include fresh frozen plasma and factor XI concentrate where available.
Factor XIII deficiency produces a unique bleeding phenotype characterized by delayed bleeding after initial hemostasis, poor wound healing, and recurrent miscarriage. Factor XIII cross-links fibrin strands, stabilizing the clot and making it resistant to fibrinolytic degradation. Without this cross-linking, clots form initially but break down prematurely. A characteristic presentation is umbilical stump bleeding in neonates, occurring days after cord separation. Intracranial hemorrhage risk is elevated, affecting up to 30 percent of untreated patients. Standard coagulation tests including PT and aPTT are normal because clot formation proceeds normally. The clot solubility test, in which clots formed in factor XIII deficiency dissolve in 5 molar urea while normal clots resist dissolution, provides a screening test. Treatment involves factor XIII concentrate prophylaxis given monthly due to the long half-life.
Fibrinogen disorders include afibrinogenemia with complete absence, hypofibrinogenemia with reduced levels, and dysfibrinogenemia with qualitatively abnormal fibrinogen that may cause bleeding, thrombosis, or neither. Afibrinogenemia is autosomal recessive and produces severe bleeding from birth including umbilical stump hemorrhage, with prolonged PT, aPTT, and thrombin time. Dysfibrinogenemia is typically autosomal dominant with variable clinical phenotype. Diagnosis requires both quantitative fibrinogen measurement and functional testing. Treatment involves fibrinogen concentrate or cryoprecipitate to maintain fibrinogen levels during bleeding episodes or procedures.
Rare factor deficiencies involving factors II, V, VII, and X produce variable bleeding phenotypes generally milder than severe hemophilia. Factor VII deficiency is notable for having the shortest half-life among coagulation factors, making it the first to decline in vitamin K deficiency or warfarin therapy. Combined factor V and VIII deficiency results from mutations in genes involved in intracellular factor trafficking rather than the factors themselves. These autosomal recessive conditions require specific factor replacement or fresh frozen plasma for treatment. Inherited vitamin K-dependent factor deficiency (VKCFD) involves mutations in the gamma-carboxylation pathway affecting all vitamin K-dependent factors simultaneously.
Panel A: Comparison of factor XI deficiency characteristics including inheritance, population prevalence, bleeding pattern, and poor correlation with factor level. Panel B: Factor XIII function in fibrin cross-linking and consequences of deficiency including delayed bleeding and wound healing problems. Panel C: Fibrinogen disorders spectrum from afibrinogenemia through hypofibrinogenemia to dysfibrinogenemia with clinical manifestations. Panel D: Overview of rare factor deficiencies showing inheritance patterns, factor half-lives, and treatment options.
---
### VIII. Acquired Coagulation Disorders
Vitamin K deficiency produces coagulopathy through impaired gamma-carboxylation of the vitamin K-dependent factors II, VII, IX, and X, as well as proteins C and S. Dietary deficiency rarely causes problems alone in adults given intestinal bacterial synthesis and hepatic stores, but may develop with prolonged starvation or total parenteral nutrition without supplementation. Malabsorption from cholestatic liver disease, celiac disease, or short bowel syndrome prevents uptake of this fat-soluble vitamin. Antibiotic therapy eliminates gut flora that produce vitamin K. Warfarin intentionally inhibits vitamin K recycling to produce therapeutic anticoagulation. Laboratory findings show prolonged PT first since factor VII has the shortest half-life, followed by aPTT prolongation as other factors decline. Treatment involves vitamin K administration orally for mild deficiency or intravenously for urgent correction, with fresh frozen plasma or prothrombin complex concentrate for immediate hemostasis.
Liver disease produces complex coagulopathy through multiple mechanisms affecting both procoagulant and anticoagulant factors. The liver synthesizes nearly all coagulation factors except von Willebrand factor, which is endothelium-derived, and factor VIII, which is also produced by endothelium and actually increases in liver disease. Reduced clearance of activated coagulation factors and tissue plasminogen activator contributes to both bleeding and fibrinolysis. Thrombocytopenia results from splenic sequestration due to portal hypertension and decreased thrombopoietin production. Dysfibrinogenemia with abnormal sialic acid content occurs in liver disease. Importantly, the balance between procoagulant and anticoagulant factors means patients may paradoxically experience thrombosis despite abnormal coagulation tests. Standard coagulation tests are poor predictors of bleeding risk, and thromboelastography may better assess global hemostatic function.
Disseminated intravascular coagulation represents systemic activation of coagulation resulting in simultaneous thrombosis and bleeding through consumption of both coagulation factors and platelets. Triggers include sepsis as the most common cause, trauma, malignancy particularly mucin-secreting adenocarcinomas and acute promyelocytic leukemia, obstetric complications including placental abruption and amniotic fluid embolism, and transfusion reactions. The pathophysiology involves widespread thrombin generation causing microvascular fibrin deposition while consuming platelets and coagulation factors. Laboratory findings include thrombocytopenia, prolonged PT and aPTT, decreased fibrinogen, and markedly elevated D-dimer from fibrinolysis of deposited fibrin. Schistocytes on blood smear reflect mechanical hemolysis. Treatment primarily targets the underlying cause, with supportive transfusion of platelets, fresh frozen plasma, and cryoprecipitate as needed for bleeding.
Acquired hemophilia results from autoantibodies against factor VIII, producing sudden severe bleeding in patients without personal or family bleeding history. Associations include autoimmune diseases, malignancy, pregnancy and the postpartum period, and drugs, though many cases are idiopathic. Unlike congenital hemophilia, the bleeding pattern often involves soft tissue and skin hemorrhage rather than joints. Laboratory evaluation reveals prolonged aPTT not correcting with mixing study, confirming an inhibitor rather than factor deficiency. Factor VIII activity is low, and the Bethesda assay quantifies inhibitor titer. Treatment of acute bleeding requires bypassing agents including recombinant factor VIIa or activated prothrombin complex concentrate since factor VIII replacement is neutralized by the inhibitor. Immunosuppressive therapy with corticosteroids and often cyclophosphamide or rituximab aims to eradicate the autoantibody.
Panel A: Vitamin K cycle showing warfarin inhibition point and affected factors with sequential laboratory changes. Panel B: Multiple mechanisms of coagulopathy in liver disease including decreased synthesis, impaired clearance, thrombocytopenia, and dysfibrinogenemia. Panel C: Pathophysiology of DIC showing triggers, widespread thrombin generation, consumption, and laboratory findings. Panel D: Acquired hemophilia presenting features, laboratory diagnosis with non-correcting mixing study, and treatment with bypassing agents and immunosuppression.
---
### IX. Interpreting Coagulation Tests
Isolated PT prolongation with normal aPTT indicates deficiency or inhibition affecting the extrinsic pathway exclusively, since only factor VII is unique to this pathway while other factors are shared with the common pathway assessed by both tests. Factor VII deficiency may be inherited or acquired. Early vitamin K deficiency or warfarin effect produces isolated PT prolongation first because factor VII has the shortest half-life of the vitamin K-dependent factors at approximately 6 hours. Early liver disease similarly affects factor VII first for the same reason. Factor VII inhibitors are rare. The approach involves mixing studies to distinguish deficiency from inhibitor, followed by specific factor assay if deficiency is confirmed.
Isolated aPTT prolongation with normal PT indicates deficiency or inhibition affecting factors unique to the intrinsic pathway, including XII, XI, IX, VIII, prekallikrein, and high-molecular-weight kininogen. Factor VIII, IX, and XI deficiencies cause bleeding and represent hemophilia A, B, and C respectively. Factor XII deficiency paradoxically does not cause clinical bleeding despite marked aPTT prolongation because factor XII is not essential for in vivo hemostasis. von Willebrand disease secondarily reduces factor VIII levels, producing aPTT prolongation in moderate to severe cases. Heparin prolongs aPTT through antithrombin enhancement and should be excluded by history or thrombin time. Lupus anticoagulant prolongs aPTT in vitro but paradoxically causes thrombosis rather than bleeding, requiring specific phospholipid-dependent testing for diagnosis.
Both PT and aPTT prolongation indicates involvement of the common pathway or multiple factors spanning both pathways. Common pathway factors include X, V, II, and fibrinogen, with deficiency of any causing prolongation of both tests. Advanced vitamin K deficiency affects all vitamin K-dependent factors including those in both pathways. Advanced liver disease impairs synthesis of multiple factors. Disseminated intravascular coagulation consumes factors throughout the cascade. Supratherapeutic warfarin or heparin anticoagulation produces combined prolongation. Massive transfusion dilutes coagulation factors if replacement is inadequate. The thrombin time helps distinguish fibrinogen abnormalities and heparin effect from factor deficiencies.
Mixing studies provide the critical distinction between factor deficiency and inhibitor presence when coagulation tests are prolonged. Patient plasma mixed in a 1:1 ratio with normal plasma provides sufficient factors to correct deficiency-related prolongation. If the prolonged test corrects to within normal range, factor deficiency is confirmed, and specific factor assays identify the deficient factor. If the test remains prolonged after mixing, an inhibitor is present that neutralizes normal plasma factors. Specific factor inhibitors such as factor VIII autoantibodies cause immediate non-correction. Lupus anticoagulant is a phospholipid-dependent inhibitor that may show time-dependent strengthening when incubated at 37 degrees. Heparin in the sample acts as an inhibitor but can be identified by prolonged thrombin time and reversed with protamine or heparinase.
Panel A: Algorithm for isolated PT prolongation showing factor VII deficiency, early vitamin K deficiency, and early warfarin as causes with diagnostic approach. Panel B: Differential diagnosis for isolated aPTT prolongation distinguishing bleeding disorders from non-bleeding causes including factor XII deficiency and lupus anticoagulant. Panel C: Causes of combined PT and aPTT prolongation including common pathway defects, DIC, liver disease, and anticoagulant excess. Panel D: Mixing study interpretation diagram showing correction indicating deficiency versus non-correction indicating inhibitor.
---
### X. Treatment Modalities
Blood product replacement provides essential components for treating coagulation factor deficiencies and acute bleeding. Fresh frozen plasma contains all coagulation factors and is used for multiple factor deficiencies, liver disease coagulopathy, warfarin reversal when time permits, and as a source of specific factors when concentrates are unavailable. The typical dose of 10 to 15 milliliters per kilogram raises factor levels by approximately 20 to 30 percent. Cryoprecipitate, the cold-insoluble fraction of plasma, concentrates fibrinogen, factor VIII, von Willebrand factor, and factor XIII in a small volume. This product is used for hypofibrinogenemia and as second-line therapy for hemophilia A and von Willebrand disease. Platelet transfusion addresses thrombocytopenia or platelet dysfunction when bleeding occurs or procedures are needed.
Pharmacologic agents provide alternatives to blood products for specific clinical situations. DDAVP (desmopressin) releases endothelial stores of von Willebrand factor and factor VIII, producing two to five-fold increases lasting 6 to 12 hours. This agent is effective for mild hemophilia A, type 1 von Willebrand disease, and uremic bleeding, administered intravenously, subcutaneously, or intranasally. Tachyphylaxis limits repeated dosing. Antifibrinolytic agents including aminocaproic acid and tranexamic acid inhibit plasminogen activation, stabilizing clots against fibrinolysis. These agents are particularly useful for mucosal bleeding where local fibrinolysis is prominent and as adjuncts in dental procedures. Vitamin K administration treats deficiency and reverses warfarin, with oral administration appropriate for non-urgent situations and intravenous for more rapid correction.
Prothrombin complex concentrates contain concentrated vitamin K-dependent factors and provide rapid correction of warfarin anticoagulation or replacement in liver disease. Three-factor PCC contains factors II, IX, and X, while four-factor PCC adds factor VII for more complete correction. These products achieve faster and more complete reversal than fresh frozen plasma with smaller volume. Activated PCC (FEIBA) and recombinant activated factor VII serve as bypassing agents for hemophilia patients with inhibitors, generating thrombin through factor VIII/IX-independent pathways. Specific reversal agents include protamine for heparin, idarucizumab for dabigatran, and andexanet alfa for factor Xa inhibitors.
Recombinant factor products have transformed hemophilia management through improved safety and supply compared to plasma-derived products. Recombinant factors VIII and IX are produced without human plasma, eliminating viral transmission risk. Standard half-life products require frequent infusion, while extended half-life products using PEGylation, Fc fusion, or albumin fusion allow less frequent dosing for prophylaxis. Factor VIII products are used for hemophilia A and von Willebrand disease type 3. Factor IX products treat hemophilia B. Emicizumab, a bispecific antibody bridging factors IXa and X to mimic factor VIII cofactor function, provides effective prophylaxis for hemophilia A including patients with inhibitors. Gene therapy delivering functional factor genes via adeno-associated viral vectors represents the frontier of hemophilia treatment, with early approvals showing durable factor expression.
Panel A: Comparison of blood products showing contents, indications, and typical dosing for fresh frozen plasma, cryoprecipitate, and platelets. Panel B: Mechanism and clinical applications of DDAVP showing endothelial release of von Willebrand factor and factor VIII with response timeline. Panel C: Prothrombin complex concentrate composition comparing three-factor and four-factor products with clinical uses. Panel D: Overview of recombinant products and novel therapies for hemophilia including standard and extended half-life factors, emicizumab, and gene therapy.
---
## Summary
- Hemostasis involves primary platelet plug formation and secondary fibrin clot stabilization through the coagulation cascade
- Primary hemostatic defects produce mucocutaneous bleeding with immediate onset, while secondary defects cause deep tissue and joint bleeding with delayed onset
- Thrombocytopenia results from decreased production, increased destruction as in ITP, or sequestration, with mechanism determining treatment
- ITP treatment progresses from observation through steroids, IVIG, TPO agonists, and splenectomy based on severity
- Heparin-induced thrombocytopenia causes thrombosis despite low platelets, requiring immediate heparin cessation and alternative anticoagulation
- von Willebrand disease is the most common inherited bleeding disorder, treated with DDAVP for type 1 and vWF concentrate for severe types
- Hemophilia A and B are X-linked factor VIII and IX deficiencies causing hemarthrosis, treated with factor replacement or emicizumab
- DIC involves systemic coagulation activation with consumption causing simultaneous thrombosis and bleeding, requiring treatment of the underlying cause
- PT prolongation alone suggests factor VII or early vitamin K deficiency; aPTT alone suggests factors VIII, IX, XI, or lupus anticoagulant
- Mixing studies distinguish factor deficiency (corrects) from inhibitors (does not correct)
---
## Key Terms
| Term | Definition |
|------|------------|
| Primary hemostasis | Platelet plug formation involving vasoconstriction, adhesion, activation, and aggregation |
| Secondary hemostasis | Fibrin clot formation through the coagulation cascade generating thrombin |
| PT/INR | Prothrombin time assessing extrinsic and common pathway, standardized as international normalized ratio |
| aPTT | Activated partial thromboplastin time assessing intrinsic and common pathway |
| ITP | Immune thrombocytopenia caused by antiplatelet autoantibodies |
| HIT | Heparin-induced thrombocytopenia causing thrombosis through anti-PF4/heparin antibodies |
| Hemarthrosis | Bleeding into joints characteristic of hemophilia |
| DDAVP | Desmopressin releasing endothelial von Willebrand factor and factor VIII stores |
---
*This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*